Fig. 6: Evaluating patient-specific CAR T cell responses.
a, The whole scanning (top left), 3D view (top right) and 2D view (bottom) of patient-specific bone marrow niche on-chip built with PD7606 bone marrow mononuclear cells after 9-day on-chip culture. Representative images were from one of the three technical replicates with similar results (n = 3). b, On-chip response curves of patient-specific leukaemia chips under treatment of donor matched 4-1BBζ-CAR T cells (dose of 10,000 CAR T cells). Three patients were tested, that is, PD7606, PD7813 and PD8012. Data were collected from three technical replicates (n = 3), where each chip has eight random fields quantified (n = 24 images). One-way ANOVA followed by Tukey’s post hoc test, mean and s.e.m. c, Quantification (top) and representative images (bottom) of surface expression of CD69 on CAR T cell from matched patient-specific leukaemia chips. CAR T cell from chips prepared with healthy donor-derived bone marrow mononuclear cells (HD BM) was used as the control (Extended Data Fig. 8d). Data were collected from three technical replicates (n = 3), where each chip has ten random fields quantified (n = 10 images) with >200 T cells. Unpaired, two-sided, Student’s t-test, mean and s.e.m. d, ELISA measured IFNγ secretions from patient-specific leukaemia chips treated with donor-matched CAR T cell (CAR) and Mock T cell (Mock) at different time points (days 0, 2, 5 and 7). Data were collected from three technical replicates (n = 3). Two-way ANOVA followed by Tukey’s post hoc test, mean and s.e.m.
